Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study
奥希替尼与对照第一代表皮生长因子受体酪氨酸激酶抑制剂作为EGFR突变晚期非小细胞肺癌患者一线治疗的疗效比较：一项中国多中心真实世界队列研究
期刊:Translational Lung Cancer Research
影响因子:3.5
doi:10.21037/tlcr-23-577
Zhang, Dongming; Liu, Xiaoyan; Shen, Fangfang; Zhao, Dahai; Shi, Yuequan; Zhang, Haoran; Liu, Jia; Gao, Xiaoxing; Chen, Minjiang; Zhao, Jing; Zhong, Wei; Gao, Junzhen; He, Min; Liu, Yonggang; Yang, Xiaoling; Qin, Jianwen; Tang, Yuling; Mu, Xinlin; Gu, Yangchun; Zhang, Shucai; Chen, Xueqin; Pang, Li; Meng, Qingwei; Guo, Ye; Zhang, Yuhui; Li, Wei; Xing, Puyuan; Cheng, Yuan; Xin, Tao; Li, Qingxia; Li, Yu; Chen, Jun; Gao, Feng; Jin, Bo; Rossi, Antonio; Adachi, Hiroyuki; Guerrera, Francesco; Husain, Hatim; Xu, Yan; Wang, Mengzhao
